Sangamo BioSciences (SGMO) PT Raised to $35 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Sangamo BioSciences (SGMO) PT Raised to $33 at Jefferies
February 23, 2018 8:58 AM ESTJefferies raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $33.00 (from $18.00) while maintaining a Buy rating.
... MoreSangamo BioSciences (SGMO) PT Raised to $32 at Piper Jaffray, Remains Positive Citing Broadening Platform
February 22, 2018 4:26 PM ESTPiper Jaffray raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $32.00 (from $25.00) while maintaining a Overweight rating.
... MoreSangamo BioSciences (SGMO) PT Raised to $39 at Wells Fargo
February 22, 2018 12:23 PM ESTWells Fargo raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $39.00 (from $30.00) while maintaining a Outperform rating.
The analyst likes the company's competitive advantage in gene-editing, which is attributed to years of experience with single loci targeting and suspects it should be... More
Sangamo BioSciences (SGMO) PT Raised to $30 at Barclays
February 22, 2018 11:56 AM ESTBarclays raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $30.00 (from $20.00) while maintaining a Overweight rating.
Analyst Gena Wang ups the price target to reflect technology capabilities at the company and progress in clinical programs. The analyst says the with... More
Sangamo Therapeutics (SGMO) Tops Q4 EPS by 3c
February 22, 2018 7:22 AM ESTSangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.15), $0.03 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $13.1 million versus the consensus estimate of $11.43 million.
For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.
... More